Background. We compared survival between videoassisted thoracoscopic surgery (VATS) and thoracotomy approaches to lobectomy for non-small cell lung cancer.
Methods. Overall survival of patients who had lobectomy for any stage non-small cell lung cancer without previous chemotherapy or radiation from 1996 to 2008 was evaluated using the Kaplan-Meier method and multivariate Cox analysis. Propensity scoring was used to assess the impact of selection bias.
Results. Overall, 1,087 patients met inclusion criteria (610 VATS, 477 thoracotomy). Median follow-up was not significantly different between VATS and thoracotomy patients overall (53.4 versus 45.4 months, respectively; p [ 0.06) but was longer for thoracotomy for surviving patients (102.4 versus 67.9 months, p < 0.0001). Thoracotomy patients had larger tumors (3.9 ± 2.3 versus 2.8 ± 1.5 cm, p < 0.0001), and more often had higher stage cancers (50% [n Conclusions. The thoracoscopic approach to lobectomy for non-small cell lung cancer does not result in worse long-term survival compared with thoracotomy. obectomy is considered the oncologically optimal treatment for patients with early stage non-small cell lung cancer (NSCLC) [1, 2] . Use of video-assisted thoracoscopic surgery (VATS) to perform lobectomy has been shown to have less morbidity compared with thoracotomy [3] [4] [5] [6] [7] [8] . Although a VATS approach was initially typically restricted to small, very early stage tumors [9] , studies have shown VATS can be safely and effectively utilized to resect larger and more advanced tumors [10] [11] [12] [13] [14] . However, despite some increase in recent years, a VATS approach is used in the minority of lobectomies performed in the United States [15, 16] .
One potential reason for the low utilization of the thoracoscopic approach is concern that it compromises the oncologic principles of anatomic resection and complete lymphadenectomy, and thus long-term survival [17] . Although a VATS approach allows an equivalent number of lymph node stations to be assessed compared with thoracotomy [18] , some centers have reported that their use of VATS led to harvesting a smaller number of lymph nodes than thoracotomy [19, 20] . Indeed, two national studies have shown that a VATS approach is associated with lower rates of upstaging from clinical N0 to pathologic N1 or N2 compared with thoracotomy [21, 22] . Inadequate lymph node evaluation could lead to understaging and undertreatment, and hence, to potentially worse survival.
Despite these concerns, institutional series that directly compared VATS and thoracotomy have shown that longterm survival after a VATS approach is equivalent and perhaps better than thoracotomy [23] [24] [25] [26] [27] [28] [29] . Systematic reviews have shown similar results [30, 31] . However, because VATS is a relatively new technique, most of the institutional studies have a relatively small number of patients and somewhat short long-term follow-up, which reduces their power to detect differences between the surgical approaches and also limits their ability to account for a potential selection bias of a VATS approach being utilized for more favorable tumors. The systematic reviews and metaanalyses increase the power to evaluate differences, but are not necessarily able to account for potential selection bias in their included studies [30] . Although there have been advocates for the performance of a randomized prospective trial comparing VATS and open lobectomy [17] , such a trial is unlikely to be performed owing to logistical issues and lack of surgeon equipoise.
The purpose of this study of this study was to further evaluate the oncologic efficacy of a VATS approach to lobectomy for NSCLC by utilizing a large institutional experience with both VATS and thoracotomy techniques so that the impact of selection bias could be adequately evaluated.
Patients and Methods
After obtaining Institutional Review Board approval, the records of all patients who underwent curative-intent surgery without previous chemotherapy or radiation for NSCLC at Duke University Medical Center between the years 1996 and 2008 were reviewed. Only patients who underwent standard lobectomy or bilobectomy were included; patients who had sleeve resection or concomitant chest wall resection were excluded. Patients who presented with synchronous primary tumors or had a prior history of lung cancer were also excluded from this study.
A retrospective review was conducted to document demographics, preoperative characteristics and comorbidities, the histology and stage of disease, and intraoperative details. All operative and pathology reports were reviewed in detail to confirm stage and operative resection. Stage was recorded based on the American Joint Committee on Cancer, seventh edition, staging system; patients treated during times of earlier staging editions were recoded according to the seventh edition definitions [32] . Because only patients who did not receive induction therapy were included, pathologic stage was listed in all patients. Deaths were captured by record review and through the Social Security Death Index database. Operative mortality included deaths that occurred within 30 days after operation and those that occurred later but during the initial hospitalization.
Thoracoscopic lobectomy was performed without any rib spreading with the thoracoscope placed in the eighth intercostal space in the midaxillary line and a 4-cm to 5-cm anterior utility incision in the fifth intercostal space; a posterior 1-cm utility incision in the tenth intercostal space was used in some cases. Thoracotomy for most patients was through the standard posterolateral approach with sparing of the serratus muscle. Patients who initially underwent attempted thoracoscopic lobectomy and then were converted to thoracotomy were considered in the statistical analysis to have had a thoracoscopy approach. Mediastinal lymph node dissection was done for all lobectomies regardless of approach, and generally included stations 2R, 4R, and 7 for right-sided tumors and 5 and 7 for left-sided tumors.
Adjuvant chemotherapy or radiation therapy was considered at the discretion of the treating physicians according to National Comprehensive Cancer Network guidelines [2] . Postoperative surveillance was surgeondependent and not standardized but typically consisted of a computed tomography scan of the chest every 6 to 12 months for at least 5 years after resection.
Overall survival was calculated from the date of surgery to date of death. Overall survival included all deaths from any cause in the follow-up period, whereas patients alive were censored at the last available follow-up. To compare survival between patients who had lobectomy through thoracotomy and VATS approaches, survival curves were initially constructed according to the KaplanMeier approach and compared using the log rank test. Subsequently, a multivariable Cox proportional hazard model for survival was fitted. Adjustment in the multivariate analysis was performed for the covariates of operative approach (thoracotomy versus VATS), age, tumor stage, and sex. The selected variables were chosen because they were thought to likely have the highest potential effect on survival of all the available variables.
The impact of selection bias was assessed using propensity scoring to compare survival between operative approaches when patients who were very likely to have either a thoracotomy or a VATS approach were removed from the analysis. Propensity scores were calculated using a logistic regression model with operative approach as the outcome and age, sex, year of surgery, tumor size, and individual TNM statuses as potential predictors. Only patients with propensity scores between 0.20 and 0.80 were then included in subsequent survival analysis, which was performed as described above.
Continuous data are presented as mean AE SD unless otherwise noted. Categorical variables are presented as frequency and percentages. Cox multivariate results are presented as hazard ratios and 95% confidence intervals (CI). Comparisons of patient characteristics between thoracotomy and VATS surgical approaches were performed using the c 2 test for categorical variables, the two-sample unpaired t test for normally distributed continuous variables, and the Kruskal-Wallis test for nonnormally distributed continuous variables. A twotailed p value of less than 0.05 was considered significant. The SAS 9.2 statistical package (SAS Institute, Cary, NC) and R 2.15.1 (R Foundation for Statistical Computing, Vienna, Austria) software were used for statistical analyses.
Results
During the study period, 1,087 patients, 610 VATS (56%) and 477 thoracotomy (44%), underwent lobectomy for NSCLC and met all inclusion criteria. Demographics, baseline characteristics, and comorbid conditions of the VATS and thoracotomy patients are shown in Table 1 . A higher percentage of patients were male and pulmonary function measurements were somewhat worse in the thoracotomy group, whereas a higher percentage of patients in the VATS group had hypertension. Age and the incidences of coronary artery disease, diabetes mellitus, cerebrovascular disease, congestive heart failure, and renal insufficiency were similar between the two groups. In the entire cohort, the 5-year survival of VATS patients was 57.5% (95% CI: 53.5% to 61.7%), which was significantly better than the 43.1% (95% CI: 38.8% to 47.9%) 5-year survival of the thoracotomy patients (p < 0.001, Fig 1) . Thoracotomy approach predicted worse survival in multivariate survival analysis, as did increasing age, higher pathologic stage, and male sex (Table 3) .
Propensity Score Analysis
The logistic regression model that calculated propensity scores using approach (thoracotomy or VATS) as outcome with age, sex, year of surgery, tumor size, and individual TNM statuses as predictors showed good predictive capacity (c ¼ 0.85). Excluding patients with scores lower than 0.20 (high chance of undergoing VATS) and higher than 0.80 (high chance of undergoing thoracotomy) resulted in a subgroup of 560 patients with a predicted preoperative chance of undergoing thoracotomy between 20% and 80%. In this subgroup, 311 patients (56%) underwent VATS and 249 (44%) underwent thoracotomy.
Demographics, baseline characteristics, and pathologic details for the VATS and thoracotomy patients in this subgroup are shown in Table 4 . The patients in the two groups had similar ages, sex distribution, pulmonary function measurements, and staging mediastinoscopy use. The patients in the two groups also had similar tumor sizes and similar distributions of both overall stage as well as individual T, N, and M statuses. Values are mean AE SD or n (%).
VATS ¼ video-assisted thoracoscopic surgery. Fig 2) . Operative approach did not impact survival in multivariate survival analysis of this cohort, whereas increasing age, pathologic stage, and male sex predicted worse survival ( Table 5 ). The 5-year survival of patients with stage I disease was not different between the two approaches (VATS 60.7% versus thoracotomy 54.8%, p ¼ 0.5).
Comment
Both single-center and multiple-institution studies have demonstrated short-term benefits of a VATS approach to lobectomy over a thoracotomy, including less overall morbidity and shorter hospital stays [7, 8] . Several institutional series have shown that long-term survival after a VATS approach to lobectomy for lung cancer is equivalent and perhaps better than thoracotomy, although many of these studies are limited by small sample sizes and potential bias of a minimally invasive approach being selected for more favorable tumors [23] [24] [25] [26] [27] [28] [29] . In this current study that included more than 600 patients undergoing VATS lobectomy for NSCLC, we found that a VATS approach did not result in worse long-term survival compared with a thoracotomy. These results held even when propensity score analysis was used to create groups of patients who were well-matched in terms of age, pulmonary function, sex, tumor size, and cancer stage.
The gold standard method of proving that a VATS lobectomy for NSCLC is not oncologically inferior to thoracotomy would be the performance of a large prospective multicenter randomized trial [17] . Unfortunately, logistical issues associated with conducting a randomized trial of surgical patients and lack of equipoise for surgeons who favor either approach make it very unlikely such a trial will happen. Both this current study and previous studies are reassuring that a minimally invasive approach with VATS does not sacrifice oncologic efficacy. However, the concerns regarding whether a VATS approach for NSCLC is oncologically equivalent to thoracotomy are principally based on whether a VATS approach allows as complete a hilar and mediastinal lymph node dissection as thoracotomy. Several singleinstitution studies have shown that fewer lymph nodes were harvested after a VATS lobectomy compared with thoracotomy, and a VATS approach was also found to be associated with less nodal upstaging than thoracotomy in two national studies [19] [20] [21] [22] . Although the results of our study provide further evidence that a VATS approach does not compromise patient survival, it must be emphasized that surgeons performing a VATS lobectomy for NSCLC must accomplish lymph node removal that is equivalent to what they would accomplish by thoracotomy. Ultimately, patient outcomes are likely more dependent on whether a surgeon performs a good oncologic procedure, regardless of the specific approach.
In addition to short-term perioperative benefits, a VATS approach to lobectomy for NSCLC has other potential advantages over a thoracotomy. Several studies have shown that the benefits of a minimally invasive approach are especially pronounced in higher risk patients, including the elderly and patients with poor pulmonary function [3, 6, 16, 33, 34] . A minimally invasive approach may, therefore, allow safe surgical resection of early stage NSCLC in patients who traditionally may have been considered to be inadequate candidates for resection through thoracotomy. In addition, the reduced perioperative morbidity associated with a VATS approach may allow more patients to be treated with adjuvant chemotherapy when indicated. In one study, a VATS approach was associated with an overall higher compliance rate and fewer delayed or reduced doses of chemotherapy in patients receiving adjuvant chemotherapy compared with thoracotomy after lobectomy for NSCLC [35] . Another study described a similar high rate of successful adjuvant chemotherapy completion after VATS lobectomy [36] .
In this study, patients who underwent an initial VATS approach that was converted to thoracotomy were considered in the VATS group so that survival was evaluated according to the original treatment intention. This analytical method could both positively and negatively bias the results associated with a VATS approach. If the need to convert from VATS to thoracotomy is associated with worse outcomes because the reason for conversion was associated with patient instability, then considering the conversion patients in the VATS group prevents bias that would favor the VATS group. However, performing a thoracotomy for a conversion may remove what some surgeons believe are the oncologic limitations of the VATS approach, and thus unfairly favorably positively bias the VATS group if the VATS approach is truly inferior. Although the impact of either bias in this study may not be significant, given the low conversion rate of 3.6%, maintaining the analysis according to treatment intention was considered most appropriate considering that any impact on short-term morbidity and mortality clearly can potentially also impact long-term mortality.
The main strengths of this study are the large cohort of patients who underwent VATS lobectomy and the extensive use of VATS lobectomy for both small stage IA tumors and larger, more advanced cancers. That allowed the use of propensity scoring to evaluate the potential impact of selection bias. Although it is impossible to completely control selection bias in a retrospective study, we were able to evaluate the impact of operative approach on survival in a cohort of more than 500 patients who were well matched in terms of both patient and cancer characteristics. However, despite the use of propensity scores, the main limitation of this study remains its retrospective nature. Imbalance between patient characteristics that were not recorded, such as whether the VATS approach was preferentially used for peripheral tumors, could bias the results. In addition, the study may be underpowered to detect small differences in survival between the two groups despite the relatively large number of patients examined. The results of this single-center study are also not necessarily generalizable to all surgeons who perform VATS lobectomy.
In conclusion, the short-term benefits of a VATS approach over a thoracotomy to accomplish lobectomy are well documented. However, concerns persist over whether a VATS approach sacrifices oncologic efficacy compared with thoracotomy. This study adds to the growing amount of evidence in the literature that a VATS approach to lobectomy for NSCLC does not compromise the long-term outcome of patient survival. Dr Berry has received support from the National Institutes of Health funded Cardiothoracic Surgical Trials Network. We also wish to thank the Duke Tumor Registry for their support in this study.
